Virtual Library

Start Your Search

Michal Ben David Hadani



Author of

  • +

    P2.14 - Targeted Therapy (ID 183)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.14-64 - Is ALK Inhibitor a Contraindication for Subsequent IVF Pregnancy? (ID 267)

      10:15 - 18:15  |  Author(s): Michal Ben David Hadani

      • Abstract
      • Slides

      Background

      Anaplastic lymphoma kinase (ALK) inhibitors drugs, such as crizotininb, are currently at the focus of treatment for ALK positive metastatic non-small cell lung cancer. Although the FDA statement that crizotinib may be detrimental to fetus development, there is no direct prohibition against the use of crizotinib during pregnancy, neither comment regarding its consumption under assisted reproductive pregnancy. Here we report, for the first time, a normal development of twins that their oocytes were aspirated while undergoing Crizotinib therapy. Furthermore, we discuss some ethical issues raises from this report. Our report along with the rapidly improvement of the ALK inhibitors therapies, raises ethical issues such as, the debate around the right for parenthood while having a progressive uncurable disease and the right for proceeding an assistant reproductive therapy while treated with biological therapies.

      figure 1.jpgfigure 2.jpg

      Method

      "Section not applicable" - I am submitting a case report

      Result

      "Section not applicable" - I am submitting a case report

      Conclusion

      "Section not applicable" - I am submitting a case report

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.